02:47 , Feb 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Expansion into TNBC

With an RNA-binding small molecule that sensitizes HER2-negative cancers to Herceptin, Matt Disney’s latest study adds to the growing arsenal of preclinical therapies against triple-negative breast cancer. The only problem is the molecule may run...
22:35 , Jan 9, 2019 |  BC Innovations  |  Translation in Brief

T cells: Life after exhaustion?

Weizmann Institute of Science and Netherlands Cancer Institute (NKI) scientists have shown dysfunctional T cells are not as "exhausted" as previously thought, but display proliferative activity and tumor recognition. In a Cell paper published on...
17:04 , Dec 20, 2018 |  BC Innovations  |  Translation in Brief

Beyond T cell counts

While strategies to increase the efficacy of immune checkpoint inhibitors have largely been focused on boosting overall T cell count in the tumor microenvironment, researchers at the Netherlands Cancer Institute (NKI) found that antigen specificity...
23:28 , Jun 7, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: May 2018

New Therapeutic Targets and Biomarkers: May 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during May 2018. Therapeutic targets are defined as any protein, gene or other...
19:34 , May 17, 2018 |  BC Innovations  |  Finance

Europe’s piece of the pie

With China’s rising infrastructure for life science innovation and the unabated growth of U.S. science, Europe has two cards to play that can help it compete globally: expertise in key core technologies and its centralized...
23:29 , May 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Enterovirus Cell culture and mouse studies suggest inhibiting KREMEN1 alone or in combination with KREMEN2 could help treat coxsackie viral infections. An insertional mutagenesis screen in a human cell line challenged with the coxsackie...
23:34 , Jan 25, 2018 |  BC Innovations  |  Targets & Mechanisms

Unexpected combinations

Two studies are prompting a rethink of how combination therapies target cancer at both the level of individual cells, and across a patient population. The papers are pushing drug developers to parse data from preclinical...
05:03 , Jan 19, 2018 |  BC Week In Review  |  Company News

Desktop Genetics gets license to CRISPR analysis web tool

Desktop Genetics Ltd. (London, U.K.) received exclusive worldwide rights to TIDE (Tracking of Indels by DEcomposition) technology from the Netherlands Cancer Institute. TIDE is a web tool that detects genome editing-mediated indels to quantitatively assess...
23:21 , Nov 30, 2017 |  BC Week In Review  |  Company News

Neon licenses gene therapy IP from Netherlands Cancer Institute

In October, immuno-oncology company Neon Therapeutics Inc. (Cambridge, Mass.) exclusively licensed IP and know-how from the Netherlands Cancer Institute (Amsterdam, the Netherlands) to develop preclinical gene therapy candidate NEO-PTC-01. Neon plans to start a Phase...
23:34 , Nov 2, 2017 |  BC Innovations  |  Targets & Mechanisms

Golden State of DUBs

Four papers in the last two weeks describing inhibitors of the ubiquitin-regulating protein USP7 could signal an important breakthrough in the ability to drug DUBs, a class of enzymes that has been stubbornly intractable until...